Abstract LBA94
Background
Growing pre- and clinical evidence show that short-term fasting (STF) of 48 to 72 hours around each chemotherapy (CTX) may potentially support CTX, reducing toxicity and adverse effects.
Methods
This randomised multi-center study of breast cancer (BC) patients undergoing CTX was conducted to assess feasibility and health-related quality of life (HRQoL) for 60-72 h STF compared to a plant-based low-sugar diet (PBD). HRQoL was assessed by FACT-G, FACIT-F (fatique) and further questionnaires at baseline (V0) and after each CTX session (day 7) as well as after 4 (V1) and 6 (V2) months. Laboratory parameters were collected at the same time points. CTX consisted of 4 x AC or EC, followed by either 12 x paclitaxel (Pac) (80 mg/m2) weekly or 4 x docetaxel (Doc) three-weekly (100 mg/m2).
Results
106 patients were included in the study and randomized to STF (n=52) or PBD (n=56). 90 (84.9%) patients obtained AC/EC -> Pac and 16 (15.1%) AC/EC -> Doc. The 27-item generic CORE questionnaire FACT-G measuring four domains of HRQoL (physical, social/family, emotional, and functional well-being) showed no significant difference at V0 (STF 82.9; PBD 81.9; p=0.523). STF-patients' FACT-G improved at day 7 from cycle to cycle versus PBD-patients. At cycle 4, day 7, FACT-G for STF was 78.3 (std. error (SE) 2.7; 95% C.I. 72.8-83.7) and for PBD 69.3 (SE 2.6: 95% C.I. 64.0-74.6). The difference 9.0 (SE 3.8) was statistically significant (p = 0.021) and clinically relevant (9.0 > minimal important difference (MID = 5)). The differences between the corresponding FACIT-F Trial Outcome Index resp. Total FACIT-F at cycle 4 day 7 were 13.1 (SE 4.7) resp. 15.8 (SE 5.6), both in favor of STF (> MID= 6, p < 0.007). The mean Total Hospital Anxiety and Depression Score (HADS-T) shows mental distress (HADS-T ≥ 13) for both STF and PBD at V0 and cycle 4 day 7 with no statistically significant differences. At V0 mean platelet counts (MPCs) were 256.6 (SE 10.8) for STF and 266.2 (SE 9.9) for PBD (p=0.512). At cycle 4 day 7 MPCs were 209.5 (SE 13.7) for STF and 177.7 (SE 12.3) for PBD.
Conclusions
Neither STF nor PBD showed serious adverse effects in the studied population. STF during chemotherapy is well tolerated and appears to improve QoL and fatigue during chemotherapy compared to a plant-based low-sugar diet.
Clinical trial identification
NCT03162289 on 22 May 2017.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
This study is funded by a private sponsor (G. Müller, Munich, Germany) and a grant from the Günter and Regine KelmFoundation (Zurich, Switzerland).
Disclosure
D.A. Koppold: Financial Interests, Personal, Ownership Interest: Academy for Integrative Fasting (AIF) GbR; Financial Interests, Personal, Advisory Role: Fastic (Mobile App); Financial Interests, Personal, Leadership Role: ÄGHE (Ärztegesellschaft Heilfasten und Ernährung e.V.). C. Kessler: Financial Interests, Personal, Advisory Board: Bruno Zimmer. E. Hanslian: Non-Financial Interests, Personal, Leadership Role: ÄGHE (Ärztegesellschaft Heilfasten und Ernährung e.V.)). A. Michalsen: Financial Interests, Personal, Ownership Interest: Academy for Integrative Fasting (AIF) GbR, Salufast GmbH; Non-Financial Interests, Personal, Leadership Role: ÄGHE (Ärztegesellschaft Heilfasten und Ernährung e.V.). All other authors have declared no conflicts of interest.
Resources from the same session
2030O - Remote symptom monitoring with electronic patient-reported outcomes (ePROs) during treatment for metastatic cancer: Results from the PRO-TECT trial (Alliance AFT-39)
Presenter: Ethan Basch
Session: Proffered Paper session - Supportive and palliative care
Resources:
Abstract
Slides
Webcast
2031O - Randomized trial of a telephone-based weight loss intervention in overweight and obese patients (pts) with breast cancer (BC): The MEDEA trial
Presenter: Ines Vaz Luis
Session: Proffered Paper session - Supportive and palliative care
Resources:
Abstract
Slides
Webcast
Invited Discussant 2030O and 2031O
Presenter: Anne Letsch
Session: Proffered Paper session - Supportive and palliative care
Resources:
Webcast
Q&A
Presenter: All Speakers
Session: Proffered Paper session - Supportive and palliative care
Resources:
Slides
Webcast
LBA95 - Anamorelin and weight gain in patients with advanced non-small cell lung cancer (NSCLC) and cachexia: Efficacy and safety in the multinational phase III SCALA program
Presenter: David Currow
Session: Proffered Paper session - Supportive and palliative care
Resources:
Abstract
Slides
Webcast
Invited Discussant LBA94 and LBA95
Presenter: Jann Arends
Session: Proffered Paper session - Supportive and palliative care
Resources:
Slides
Webcast
Q&A
Presenter: All Speakers
Session: Proffered Paper session - Supportive and palliative care
Resources:
Slides
Webcast